The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Venetoclax plus dose-adjusted R-EPOCH for Richter’s: results of the CRC043 trial
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the CRC043 trial (NCT03054896), a Phase II study of venetoclax in combination with dose-adjusted R-EPOCH for patients with Richter’s syndrome. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
